Neuroendocrine tumors in Panama: A nationwide database analysis

Cukier,Moises; Vergara,Ruth; Mendez‑Rios,Jorge D.; Castillo,Omar; Barrera,Irma; Tello,Eliecer; El Achtar,Olivia; Loo,Yong; Tapia,Hector; Perez,Guadalupe; Peña,Maximino

doi:10.3892/mco.2021.2319

Neuroendocrine tumors in Panama: A nationwide database analysis

Authors:
- Moises Cukier
- Ruth Vergara
- Jorge D. Mendez‑Rios
- Omar Castillo
- Irma Barrera
- Eliecer Tello
- Olivia El Achtar
- Yong Loo
- Hector Tapia
- Guadalupe Perez
- Maximino Peña
View Affiliations

Affiliations: Department of Surgical Oncology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama, Department of Pathology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama, Department of Genetics and Cytogenetics, Caja de Seguro Social, Panama City, Panama 0824, Republic of Panama, Department of Medical Oncology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama, Department of General Surgery, Caja de Seguro Social, Panama City, Panama 0824, Republic of Panama, Department of Radiology and Interventionism, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama, Department of Endocrinology, Caja de Seguro Social, Panama City, Panama 0824, Republic of Panama, Department of Gastroenterology, Instituto Oncologico Nacional, Panama City, Panama 0816, Republic of Panama
Published online on: June 11, 2021 https://doi.org/10.3892/mco.2021.2319
Article Number: 157
Copyright : © Cukier et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroendocrine tumors (NETs) comprise a heterogenous group of rare malignancies, which are increasing in incidence worldwide. To further understand the epidemiology of NETs in the Republic of Panama, the present study used two study groups, which included patients from several hospitals and clinics throughout the country, who were referred to the three largest national reference centers: The Complejo Hospitalario Metropolitano, Hospital Santo Tomas and Instituto Oncologico Nacional. These two groups comprised a retrospective cohort, which included cases reported between 2016 and 2017, and a second cohort, which was retrospective, but data were continuously collected from patients diagnosed with NETs between 2018 and 2019. Data from 157 patients with NETs reported that 83% of patients were in the 40‑80 years old age group. The majority of cases (46%) presented as grade G1 tumors, while 29% were G3. Computerized tomography scans with contrast, and analysis of the Ki‑67 biomarker and immunohistology markers (chromogranin A and synaptophysin) was performed in the majority of the cases. The results revealed that the most frequent anatomical sites for the primary tumor were the colorectum (17.2%), pancreas (12.7%) and stomach (12.1%), and the most frequent organ with metastasis was the liver, accounting for 34% of all cases. In conclusion, the present study is the first comprehensive study of NET in Panama to the best of our knowledge, which provides evidence of the demographic characteristics of the population, clinical features and overall survival for the affected population in this Central American country.

View Figures

View References

1	Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, Wang JB, Chen QY, Lin M, Tu RH and Huang CM: Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database. Eur J Surg Oncol. 44:1628–1633. 2018.PubMed/NCBI View Article : Google Scholar
2	Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S and Anthony LB: Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget. 9:19245–19254. 2018.PubMed/NCBI View Article : Google Scholar
3	Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T and Yao JC: Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3:1335–1342. 2017.PubMed/NCBI View Article : Google Scholar
4	Fraenkel M, Faggiano A and Valk GD: Epidemiology of neuroendocrine tumors. Front Horm Res. 44:1–23. 2015.PubMed/NCBI View Article : Google Scholar
5	Hallet J, Law CH, Cukier M, Saskin R, Liu N and Singh S: Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes: Neuroendocrine tumor epidemiology. Cancer. 121:589–597. 2015.PubMed/NCBI View Article : Google Scholar
6	Basuroy R, Bouvier C, Ramage JK, Sissons M, Kent A and Srirajaskanthan R: Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 107:42–49. 2015.PubMed/NCBI View Article : Google Scholar
7	Basuroy R, Bouvier C, Ramage JK, Sissons M and Srirajaskanthan R: Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer. 18(1122)2018.PubMed/NCBI View Article : Google Scholar
8	O'Connor JM, Marmissolle F, Bestani C, Pesce V, Belli S, Dominichini E, Mendez G, Price P, Giacomi N, Pairola A, et al: Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol. 2:673–684. 2014.PubMed/NCBI View Article : Google Scholar
9	Pinto MP, Muñoz Medel M, Carrillo D, Retamal IN, Bravo ML, Valenzuela Y, Nervi B, Sánchez C, Galindo H, Ibañez C, et al: Chilean registry for neuroendocrine tumors: A Latin American perspective. Horm Cancer. 10:3–10. 2019.PubMed/NCBI View Article : Google Scholar
10	Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klöppel G, Komminoth P and Solcia E: Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System. 4th edition. WHO Press, Lyon, 2010.
11	Palepu J, Shrikhande SV, Bhaduri D, Shah RC, Sirohi B, Chhabra V, Dhar P, Sastry R and Sikora S: Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry. Indian J Gastroenterol. 36:445–451. 2017.PubMed/NCBI View Article : Google Scholar
12	Maric M, de Haan E, Hogendoorn SM, Wolters LH and Huizenga HM: Evaluating statistical and clinical significance of intervention effects in single-case experimental designs: An SPSS method to analyze univariate data. Behav Ther. 46:230–241. 2015.PubMed/NCBI View Article : Google Scholar
13	United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects, 2019. [cited 2020 Dec 6]. Available from: https://population.un.org/wpp/.
14	Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, et al: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9:61–72. 2008.PubMed/NCBI View Article : Google Scholar
15	Instituto Nacional de Estadística y Censo-Panamá: Estimación de la población total en la República, por provincia y comarca indígena, según sexo y grupos de edad: Al 1 de julio de, 2018. Available from: https://www.inec.gob.pa/publicaciones/Default3.aspx?ID_PUBLICACION=990&ID_CATEGORIA=17&ID_SUBCATEGORIA=45.
16	Korse CM, Taal BG, van Velthuysen ML and Visser O: Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry. Eur J Cancer. 49:1975–1983. 2013.PubMed/NCBI View Article : Google Scholar
17	Kourie HR, Ghorra C, Rassy M, Kesserouani C and Kattan J: Digestive neuroendocrine tumor distribution and characteristics according to the 2010 WHO classification: A single institution experience in lebanon. Asian Pac J Cancer Prev. 17:2679–2681. 2016.PubMed/NCBI
18	Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, et al: Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 26:1604–1620. 2015.PubMed/NCBI View Article : Google Scholar
19	Dias AR, Azevedo BC, Alban LBV, Yagi OK, Ramos MFKP, Jacob CE, Barchi LC, Cecconello I, Ribeiro U Jr and Zilberstein B: Gastric neuroendocrine tumor: Review and update. Arq Bras Cir Dig. 30:150–154. 2017.PubMed/NCBI View Article : Google Scholar
20	Lee L, Ito T and Jensen RT: Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: Recent advances and controversies. Expert Rev Anticancer Ther. 19:1029–1050. 2019.PubMed/NCBI View Article : Google Scholar
21	Al-Risi ES, Al-Essry FS and Mula-Abed WS: Chromogranin A as a biochemical marker for neuroendocrine tumors: A single center experience at royal hospital, Oman. Oman Med J. 32:365–370. 2017.PubMed/NCBI View Article : Google Scholar
22	Kim JY and Hong SM: Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts. Arch Pathol Lab Med. 140:437–448. 2016.PubMed/NCBI View Article : Google Scholar
23	Jin M, Zhou X, Yearsley M and Frankel WL: Liver metastases of neuroendocrine tumors rarely show overlapping immunoprofile with hepatocellular carcinomas. Endocr Pathol. 27:253–258. 2016.PubMed/NCBI View Article : Google Scholar
24	Liu E, Telem DA, Warner RR, Dikman A and Divino CM: The role of Ki-67 in predicting biological behavior of goblet cell carcinoid tumor in appendix. Am J Surg. 202:400–403. 2011.PubMed/NCBI View Article : Google Scholar
25	O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape UF and Plöckinger U: Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Biochemical markers. Neuroendocrinology. 90:194–202. 2009.PubMed/NCBI View Article : Google Scholar
26	Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT and Chang JS: The epidemiology of neuroendocrine tumors in Taiwan: A nation-wide cancer registry-based study. PLoS One. 8(e62487)2013.PubMed/NCBI View Article : Google Scholar
27	Edfeldt K, Björklund P, Åkerström G, Westin G, Hellman P and Stålberg P: Different gene expression profiles in metastasizing midgut carcinoid tumors. Endocr Relat Cancer. 18:479–489. 2011.PubMed/NCBI View Article : Google Scholar
28	Riihimäki M, Hemminki A, Sundquist K, Sundquist J and Hemminki K: The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 139:2679–2686. 2016.PubMed/NCBI View Article : Google Scholar
29	Klimstra D, Kloppell G, La Rosa S and Rindi G: Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours. 5th edition. WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon, pp16, 2019.